Indoxyl sulphate and kidney disease: Causes, consequences and interventions

Nephrology

Volumn 21, Issue 3, 2016, Pages 170-177

  Ellis, Robert J ^a   Small, David M ^a   Vesey, David A ^a   Johnson, David W ^a   Francis, Ross ^a   Vitetta, Luis ^b,c   Gobe, Glenda C ^a   Morais, Christudas ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c Medlab   (Australia)

Author keywords

end stage kidney disease; GFR; indoxyl sulphate; oxidative stress; uremic toxin

Indexed keywords

AST 120; INDICAN; ORGANIC ANION TRANSPORTER; PREBIOTIC AGENT; PROBIOTIC AGENT; REACTIVE OXYGEN METABOLITE; TRANSCRIPTION FACTOR NRF2; TRANSCRIPTION FACTOR RELA; URINARY TRACT AGENT;

ARTICLE; CHRONIC KIDNEY DISEASE; DIETARY FIBER; DYSBIOSIS; GLOMERULUS FILTRATION RATE; HEMODIALYSIS; HUMAN; INTESTINE FLORA; KIDNEY FAILURE; KIDNEY FIBROSIS; KIDNEY TUBULE CELL; NEPHROTOXICITY; NONHUMAN; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROTEIN RESTRICTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SULFATION; TRYPTOPHAN METABOLISM; ADMINISTRATION AND DOSAGE; ANIMAL; BACTERIUM; BLOOD; DRUG EFFECTS; KIDNEY; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; RENAL INSUFFICIENCY, CHRONIC; UPREGULATION;

ANIMALS; BACTERIA; DIET, PROTEIN-RESTRICTED; DIETARY FIBER; DYSBIOSIS; GASTROINTESTINAL MICROBIOME; GLOMERULAR FILTRATION RATE; HUMANS; INDICAN; KIDNEY; PROBIOTICS; RENAL INSUFFICIENCY, CHRONIC; UP-REGULATION; UROLOGICAL AGENTS;

EID: 84956627024     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/nep.12580     Document Type: Article

References (60)

1. Kidney Disease: Improving Global Outcomes CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. Suppl. 2013; 3: 1-150.
2. Zhang QL, Rothenbacher D,. Prevalence of chronic kidney disease in population-based studies: Systematic review. BMC Public Health 2008; 8: 117.
3. Duranton F, Cohen G, De Smet R, et al. Normal and pathologic concentrations of uremic toxins. J. Am. Soc. Nephrol. 2012; 23: 1258-1270.
4. Glassock RJ,. Uremic toxins: What are they? An integrated overview of pathobiology and classification. J. Ren. Nutr. 2008; 18: 2-6.
5. Niwa T,. Targeting protein-bound uremic toxins in chronic kidney disease. Expert Opin. Ther. Targets 2013; 17: 1287-1301.
6. Meijers BK, De Loor H, Bammens B, Verbeke K, Vanrenterghem Y, Evenepoel P,. p-Cresyl sulfate and indoxyl sulfate in hemodialysis patients. Clin. J. Am. Soc. Nephrol. 2009; 4: 1932-1938.
7. Lin CJ, Liu HL, Pan CF, et al. Indoxyl sulfate predicts cardiovascular disease and renal function deterioration in advanced chronic kidney disease. Arch. Med. Res. 2012; 43: 451-456.
8. Devine E, Krieter DH, Ruth M, Jankovski J, Lemke HD,. Binding affinity and capacity for the uremic toxin indoxyl sulfate. Toxins (Basel) 2014; 6: 416-429.
9. Jourde-Chiche N, Dou L, Cerini C, et al. Protein bound toxins-Update 2009. Semin. Dial. 2009; 22: 334-339.
10. Lee JH, Lee J,. Indole as an intercellular signal in microbial communities. FEMS Microbiol. Rev. 2010; 34: 426-444.
11. Cummings JH, Macfarlane GT,. The control and consequences of bacterial fermentation in the human colon. J. Appl. Bacteriol. 1991; 70: 443-459.
12. Niwa T, Ise M, Miyazaki T,. Progression of glomerular sclerosis in experimental uremic rats by administration of indole, a precursor of indoxyl sulfate. Am. J. Nephrol. 1994; 14: 207-212.
13. Banoglu E, Jha G, King R,. Hepatic microsomal metabolism of indole to indoxyl, a precursor of indoxyl sulfate. Eur. J. Drug Metab. Pharmacokinet. 2001; 26: 235-240.
14. Banoglu E, King RS,. Sulfation of indoxyl by human and rat aryl (phenol) sulfotransferases to form indoxyl sulfate. Eur. J. Drug Metab. Pharmacokinet. 2002; 27: 135-140.
15. Eloot S, Schepers E, Barreto DV, et al. Estimated glomerular filtration rate is a poor predictor of concentration for a broad range of uremic toxins. Clin. J. Am. Soc. Nephrol. 2011; 6: 1266-1273.
16. Enomoto A, Takeda M, Tojo A, et al. Role of organic anion transporters in the tubular transport of indoxyl sulfate and the induction of its nephrotoxicity. J. Am. Soc. Nephrol. 2002; 13: 1711-1720.
17. Akiyama Y, Kikuchi K, Saigusa D, et al. Indoxyl sulfate down-regulates SLCO4C1 transporter through up-regulation of GATA3. PLoS ONE 2013; 8: e66518.
18. Mutsaers HA, van den Heuvel LP, Ringens LH, et al. Uremic toxins inhibit transport by breast cancer resistance protein and multidrug resistance protein 4 at clinically relevant concentrations. PLoS ONE 2011; 6: e18438.
19. Macfarlane GT, Macfarlane S,. Bacteria, colonic fermentation, and gastrointestinal health. J. AOAC Int. 2012; 95: 50-60.
20. Faith JJ, Guruge JL, Charbonneau M, et al. The long-term stability of the human gut microbiota. Science 2013; 341: 1237439.
21. Tiihonen K, Ouwehand AC, Rautonen N,. Human intestinal microbiota and healthy ageing. Ageing Res. Rev. 2010; 9: 107-116.
22. Wu GD, Chen J, Hoffmann C, et al. Linking long-term dietary patterns with gut microbial enterotypes. Science 2011; 334: 105-108.
23. Qiao Y, Sun J, Ding Y, Le G, Shi Y,. Alterations of the gut microbiota in high-fat diet mice is strongly linked to oxidative stress. Appl. Microbiol. Biotechnol. 2013; 97: 1689-1697.
24. Vaziri ND, Wong J, Pahl M, et al. Chronic kidney disease alters intestinal microbial flora. Kidney Int. 2013; 83: 308-315.
25. Fukuuchi F, Hida M, Aiba Y, et al. Intestinal bacteria-derived putrefactants in chronic renal failure. Clin. Exp. Nephrol. 2002; 6: 99-104.
26. Hida M, Aiba Y, Sawamura S, Suzuki N, Satoh T, Koga Y,. Inhibition of the accumulation of uremic toxins in the blood and their precursors in the feces after oral administration of Lebenin, a lactic acid bacteria preparation, to uremic patients undergoing hemodialysis. Nephron 1996; 74: 349-355.
27. Adelibieke Y, Shimizu H, Saito S, Mironova R, Niwa T,. Indoxyl sulfate counteracts endothelial effects of erythropoietin through suppression of Akt phosphorylation. Circ. J. 2013; 77: 1326-1336.
28. Wang WJ, Cheng MH, Sun MF, Hsu SF, Weng CS,. Indoxyl sulfate induces renin release and apoptosis of kidney mesangial cells. J. Toxicol. Sci. 2014; 39: 637-643.
29. Small DM, Coombes JS, Bennett N, Johnson DW, Gobe GC,. Oxidative stress, anti-oxidant therapies and chronic kidney disease. Nephrology 2012; 17: 311-321.
30. Shimizu H, Saito S, Higashiyama Y, Nishijima F, Niwa T,. CREB, NF-kappaB, and NADPH oxidase coordinately upregulate indoxyl sulfate-induced angiotensinogen expression in proximal tubular cells. Am. J. Physiol. Cell Physiol. 2013; 304: C685-692.
31. Watanabe I, Tatebe J, Namba S, Koizumi M, Yamazaki J, Morita T,. Activation of aryl hydrocarbon receptor mediates indoxyl sulfate-induced monocyte chemoattractant protein-1 expression in human umbilical vein endothelial cells. Circ. J. 2013; 77: 224-230.
32. Owada S, Goto S, Bannai K, Hayashi H, Nishijima F, Niwa T,. Indoxyl sulfate reduces superoxide scavenging activity in the kidneys of normal and uremic rats. Am. J. Nephrol. 2008; 28: 446-454.
33. Bolati D, Shimizu H, Yisireyili M, Nishijima F, Niwa T,. Indoxyl sulfate, a uremic toxin, downregulates renal expression of Nrf2 through activation of NF-κB. BMC Nephrol. 2013; 14: 56-64.
34. Stockler-Pinto MB, Fouque D, Soulage CO, Croze M, Mafra D,. Indoxyl sulfate and p-cresyl sulfate in chronic kidney disease. Could these toxins modulate the antioxidant Nrf2-Keap1 pathway? J. Ren. Nutr. 2014; 24: 286-291.
35. Shimizu H, Yisireyili M, Nishijima F, Niwa T,. Stat3 contributes to indoxyl sulfate-induced inflammatory and fibrotic gene expression and cellular senescence. Am. J. Nephrol. 2012; 36: 184-189.
36. Shimizu H, Bolati D, Adijiang A, et al. Indoxyl sulfate downregulates renal expression of klotho through production of ROS and activation of nuclear factor-B. Am. J. Nephrol. 2011; 33: 319-324.
37. Shimizu H, Bolati D, Adijiang A, et al. Senescence and dysfunction of proximal tubular cells are associated with activated p53 expression by indoxyl sulfate. Am. J. Physiol. Cell Physiol. 2010; 299: C1110-1117.
38. Saito S, Yisireyili M, Shimizu H, Ng HY, Niwa T,. Indoxyl sulfate upregulates prorenin expression via nuclear factor-kappaB p65, signal transducer and activator of transcription-3, and reactive oxygen species in proximal tubular cells. J. Ren. Nutr. 2015; 25: 145-148.
39. Sun CY, Chang SC, Wu MS,. Uremic toxins induce kidney fibrosis by activating intrarenal renin-angiotensin-aldosterone system associated epithelial-to-mesenchymal transition. PLoS ONE 2012; 7: e34026.
40. Ng HY, Yisireyili M, Saito S, et al. Indoxyl sulfate downregulates expression of Mas receptor via OAT3/AhR/Stat3 pathway in proximal tubular cells. PLoS ONE 2014; 9: e91517.
41. Vanholder R, Schepers E, Pletinck A, Nagler EV, Glorieux G,. The uremic toxicity of indoxyl sulfate and p-cresyl sulfate: A systematic review. J. Am. Soc. Nephrol. 2014; 25: 1897-1907.
42. Cummings JH, Hill MJ, Bone ES, Branch WJ, Jenkins DJ,. The effect of meat protein and dietary fiber on colonic function and metabolism. II. Bacterial metabolites in feces and urine. Am. J. Clin. Nutr. 1979; 32: 2094-2101.
43. Niwa T, Tsukushi S, Ise M, et al. Indoxyl sulfate and progression of renal failure: Effects of a low-protein diet and oral sorbent on indoxyl sulfate production in uremic rats and undialyzed uremic patients. Miner. Electrolyte Metab. 1997; 23: 179-184.
44. Fouque D, Laville M,. Low protein diets for chronic kidney disease in non diabetic adults. Cochrane Database Syst. Rev. 2009; (3): CD001892.
45. Marzocco S, Dal Piaz F, Di Micco L, et al. Very low protein diet reduces indoxyl sulfate levels in chronic kidney disease. Blood Purif. 2013; 35: 196-201.
46. Francois IE, Lescroart O, Veraverbeke WS, et al. Effects of a wheat bran extract containing arabinoxylan oligosaccharides on gastrointestinal health parameters in healthy adult human volunteers: A double-blind, randomised, placebo-controlled, cross-over trial. Br. J. Nutr. 2012; 108: 2229-2242.
47. Chiavaroli L, Mirrahimi A, Sievenpiper JL, Jenkins DJ, Darling PB,. Dietary fiber effects in chronic kidney disease: A systematic review and meta-analysis of controlled feeding trials. Eur. J. Clin. Nutr. 2015; 69: 761-768.
48. Sirich TL, Plummer NS, Gardner CD, Hostetter TH, Meyer TW,. Effect of increasing dietary fiber on plasma levels of colon-derived solutes in hemodialysis patients. Clin. J. Am. Soc. Nephrol. 2014; 9: 1603-1610.
49. Furuse SU, Ohse T, Jo-Watanabe A, et al. Galacto-oligosaccharides attenuate renal injury with microbiota modification. Physiol. Rep. 2014; 2: e12029.
50. Lewis SJ, Heaton KW,. The metabolic consequences of slow colonic transit. Am. J. Gastroenterol. 1999; 94: 2010-2016.
51. Botsford JL, DeMoss RD,. Catabolite repression of tryptophanase in Escherichia coli. J. Bacteriol. 1971; 105: 303-312.
52. Rossi M, Klein K, Johnson DW, Campbell KL,. Pre-, pro-, and synbiotics: Do they have a role in reducing uremic toxins? A systematic review and meta-analysis. Int. J. Nephrol. 2012; 2012: 673631.
53. Rossi M, Johnson DW, Morrison M, et al. SYNbiotics Easing Renal failure by improving Gut microbiologY (SYNERGY): A protocol of placebo-controlled randomised cross-over trial. BMC Nephrol. 2014; 15: 106.
54. Niwa T,. Role of indoxyl sulfate in the progression of chronic kidney disease and cardiovascular disease: Experimental and clinical effects of oral sorbent AST-120. Ther. Apher. Dial. 2011; 15: 120-124.
55. Schulman G, Berl T, Beck GJ, et al. Randomized placebo-controlled EPPIC trials of AST-120 in CKD. J. Am. Soc. Nephrol. 2015; 26: 1732-1746.
56. Koster H, Halsema I, Scholtens E, Knippers M, Mulder GJ,. Dose-dependent shifts in the sulfation and glucuronidation of phenolic compounds in the rat in vivo and in isolated hepatocytes: The role of saturation of phenolsulfotransferase. Biochem. Pharmacol. 1981; 30: 2569-2575.
57. Niwa T, Miyazaki T, Tsukushi S, et al. Accumulation of indoxyl-beta-D-glucuronide in uremic serum: Suppression of its production by oral sorbent and efficient removal by hemodialysis. Nephron 1996; 74: 72-78.
58. Saito H, Yoshimura M, Saigo C, et al. Hepatic sulfotransferase as a nephropreventing target by suppression of the uremic toxin indoxyl sulfate accumulation in ischemic acute kidney injury. Toxicol. Sci. 2014; 14: 206-217.
59. Liu S, Wang BH, Kompa AR, Lekawanvijit S, Krum H,. Antagonists of organic anion transporters 1 and 3 ameliorate adverse cardiac remodelling induced by uremic toxin indoxyl sulfate. Int. J. Cardiol. 2012; 158: 457-458.
60. Lawrie CA, Renwick AG, Sims J,. The urinary excretion of bacterial amino-acid metabolites by rats fed saccharin in the diet. Food Chem. Toxicol. 1985; 23: 445-450.